Little sexual health research has been conducted in gay men. Anecdotally, this population seems to experience more bother related to Peyronie's Disease (PD).
To examine the impact of PD on psychosocial factors in gay versus straight men.
All PD patients who were seen in the sexual medicine clinic were included. They completed three instruments: the PD questionnaire (PDQ), Self-Esteem and Relationship (SEAR) questionnaire and a depression questionnaire (CES-D). We described demographics and sexual variables by sexual orientation. We then compared PDQ items and summary scores by sexual orientation, using a series of independent samples t-tests.
34 consecutive gay and 464 straight men were included. Age and baseline characteristics were similar between the two cohorts, with the exception that fewer gay men were partnered (56% vs 87%, p<0.01) and those with a partner had a shorter relationship duration: 109±9 months vs 262±175 months; p<0.01. For the SEAR questionnaire, gay men demonstrated a more significant psychosocial impact of PD overall with lower SEAR sums (41 vs 57, p=0.01) and a lower sexual relationship subdomain score (28 vs 47, p<0.01). 41% of gay men vs 26% of straight men had CES-D scores consistent with depression as defined by a score of ≥ 16 (p=0.09). In the PDQ domains, gay men scored less favorably with regards to bother scores (7 vs 5, p=0.03) and pain scores (8 vs 4, p=0.04).
Gay men with PD experience significantly more psychosocial impact as evidenced by less favorable SEAR sum and sexual relationship scores, CES-D scores, and PDQ pain and bother domain scores.
The psychosocial impact of PD is significant in all men, but it appears to be greater in gay men.
Andrology. 2020 Sep 10 [Epub ahead of print]
Carolyn A Salter, Bruno Nascimento, Jean-Etienne Terrier, Hisanori Taniguchi, Helen Bernie, Eduardo Miranda, Lawrence Jenkins, Elizabeth Schofield, John P Mulhall
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.